Takeda announced that their ongoing phase III ALTA-1L trial of brigatinib reduced the risk of disease progression or death in adults with advanced ALK-positive non-small cell lung cancer.
Lung Cancer Year in Review
Four cancer centers are joining forces on a new clinical trial designed to test medically tailored meals for patients with lung cancer to combat malnutrition.
Beth Eaby-Sandy, a nurse practitioner, discussed AEs associated with immunotherapy treatment in patients with lung cancer.
Atezolizumab monotherapy improved overall survival compared with platinum-based chemotherapy as a first-line treatment in patients with wild-type non–small cell lung cancer with PD-L1 expression ≥50%.